Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SANN.SW
- Price
- 13.96
- Stock movement up
- +0.40 (2.95%)
- Company name
- Santhera Pharmaceuticals Holding AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 169.00M
- Ent værdi
- 212.70M
- Pris/omsætning
- 0.99
- Pris/bog
- 3.52
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- 1.66
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 50.92%
- 3 års afkast
- 121.08%
- 5 års afkast
- 11.23%
- 10 års afkast
- -18.50%
Senest opdateret: 2025-04-16
UDBYTTE
SANN.SW betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 1.66 |
| Pris til OCF | 3.57 |
| Pris til FCF | 3.07 |
| Pris til EBITDA | 1.78 |
| EV i forhold til EBITDA | 2.24 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 0.99 |
| Pris til egenkapital | 3.52 |
| EV i forhold til salg | 1.25 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 12.11M |
| EPS (TTM) | 8.99 |
| FCF pr. aktie (TTM) | 4.86 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 170.33M |
| Bruttofortjeneste (TTM) | 162.82M |
| Driftsindkomst (TTM) | 88.82M |
| Nettoindkomst (TTM) | 101.91M |
| EPS (TTM) | 8.99 |
| EPS (1 år frem) | -3.14 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 95.59% |
| Driftsmargin (TTM) | 52.15% |
| Fortjenstmargin (TTM) | 59.83% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 16.49M |
| Nettotilgodehavender | 10.43M |
| Omsætningsaktiver i alt | 33.64M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 71.45M |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 108.25M |
| Kreditor | 14.91M |
| Kortfristet/nuværende langsigtet gæld | 26.37M |
| Summen af kortfristede forpligtelser | 53.05M |
| Sum gæld | 60.19M |
| Aktionærernes egenkapital | 48.06M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 47.35M |
| Investeringsudgifter (TTM) | 162.00K |
| Fri pengestrøm (TTM) | 55.07M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 212.07% |
| Afkast af aktiver | 94.15% |
| Afkast af investeret kapital | 141.56% |
| Kontant afkast af investeret kapital | 76.49% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 13.62 |
| Daglig høj | 14.20 |
| Daglig lav | 13.62 |
| Daglig volumen | 36K |
| Højeste gennem alle tider | 134.40 |
| 1 års analytiker estimat | 25.00 |
| Beta | 0.13 |
| EPS (TTM) | 8.99 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 23 Apr 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| SANN.SW | S&P500 | |
| Nuværende prisfald fra top notering | -89.61% | -12.29% |
| Højeste prisfald | -99.63% | -56.47% |
| Højeste efterår dato | 2 Dec 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -75.84% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 655 days | 12 days |
| Maks. tid til nyt højdepunkt | 2408 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
169.00M
Markedsværdi kategori
Small-cap
Beskrivelse
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Personale
44
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Switzerland
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming A...
27. marts 2025
Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the ...
24. marts 2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...
4. marts 2025
Ad hoc announcement pursuant to Art. 53 LR AGAMREE® is the first product to receive an agreed federal price in Germany for the treatment of all DMD patients 4 years and older, and independent of genet...
13. februar 2025
Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025Current CFO Andrew Smith to step down after five years with Santhera, an...
10. februar 2025
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...
16. januar 2025
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the Na...
16. januar 2025
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UKPratteln, Switzerland, January 14, 2025 – Santhera Pharmaceuticals (SIX: SANN) ann...
14. januar 2025
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vam...
6. januar 2025
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National Medica...
20. december 2024
Næste side